HRP20192120T1 - Postupak metronomskog doziranja kamptotecinskih prolijekova (e.g.peg-irinotekan) - Google Patents
Postupak metronomskog doziranja kamptotecinskih prolijekova (e.g.peg-irinotekan) Download PDFInfo
- Publication number
- HRP20192120T1 HRP20192120T1 HRP20192120TT HRP20192120T HRP20192120T1 HR P20192120 T1 HRP20192120 T1 HR P20192120T1 HR P20192120T T HRP20192120T T HR P20192120TT HR P20192120 T HRP20192120 T HR P20192120T HR P20192120 T1 HRP20192120 T1 HR P20192120T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- use according
- months
- days
- once
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title claims 2
- 229940002612 prodrug Drugs 0.000 title claims 2
- 229960004768 irinotecan Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000004086 maxillary sinus Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Terapijski efikasna količina farmaceutskog pripravka, naznačena time, što uključuje prolijek strukture (I):
ili njegov farmaceutski prihvatljiv oblik soli,
za uporabu u liječenju subjekta jednog ili više solidnih tumora, davanjem pripravka u doznoj količini u opsegu od oko 70 mg/m2 do oko 300 mg/m2 sa učestalošću između jednom na svakih 7 dana do jednom na svakih 30 dana tokom perioda od jednog mjeseca do šest mjeseci ili duže.
2. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što je ukupna nominalna prosječna molekulska težina polimera u opsegu od oko 10.000 do oko 60.000 daltona.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time, što se primjena događa učestalošću koja se bira između jednom na svakih 7 dana, jednom u svakih 14 dana, jednom u svakih 21 dan i jednom u svakih 28 dana.
4. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, što se tip solidnog tumora bira između tumora jajnika, dojke, grlića maternice, maksilarnog sinusa, mokraćnog mjehura, kolorektalnog, malo-staničnih pluća i ne-staničnih pluća.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što se primjenjuje tijekom perioda od jedne do nekoliko godina.
6. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, što se primjena bira između intraperitonealne, intravenske, subkutane, i intramuskularne injekcije.
7. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što se primjenjuje tijekom perioda koji se bira između jednog mjeseca, dva mjeseca, tri mjeseca, četiri mjeseca, pet mjeseci ili šest mjeseci.
8. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što je tip solidnog tumora tumor dojke.
9. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što je farmaceutski pripravak za uporabu u liječenju metastatskog raka dojke, pri čemu subjekt nije imao više od dva prethodna tretmana kemioterapeuticima na bazi antraciklina i/ili taksana.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9951608P | 2008-09-23 | 2008-09-23 | |
US10693108P | 2008-10-20 | 2008-10-20 | |
US17343309P | 2009-04-28 | 2009-04-28 | |
PCT/US2009/005284 WO2010036335A1 (en) | 2008-09-23 | 2009-09-23 | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
EP09789364.8A EP2349346B1 (en) | 2008-09-23 | 2009-09-23 | Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan) |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192120T1 true HRP20192120T1 (hr) | 2020-02-21 |
Family
ID=41268391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192120TT HRP20192120T1 (hr) | 2008-09-23 | 2019-11-26 | Postupak metronomskog doziranja kamptotecinskih prolijekova (e.g.peg-irinotekan) |
Country Status (20)
Country | Link |
---|---|
US (3) | US8906353B2 (hr) |
EP (1) | EP2349346B1 (hr) |
JP (3) | JP2012503602A (hr) |
KR (1) | KR20110063457A (hr) |
CN (1) | CN102164617A (hr) |
AU (1) | AU2009297091B2 (hr) |
CA (1) | CA2736939C (hr) |
CY (1) | CY1122208T1 (hr) |
DK (1) | DK2349346T3 (hr) |
ES (1) | ES2744975T3 (hr) |
HR (1) | HRP20192120T1 (hr) |
HU (1) | HUE047352T2 (hr) |
IL (1) | IL211888A (hr) |
LT (1) | LT2349346T (hr) |
MX (1) | MX2011003063A (hr) |
PL (1) | PL2349346T3 (hr) |
PT (1) | PT2349346T (hr) |
RS (1) | RS59607B1 (hr) |
SI (1) | SI2349346T1 (hr) |
WO (1) | WO2010036335A1 (hr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2744975T3 (es) | 2008-09-23 | 2020-02-27 | Nektar Therapeutics | Método de dosificación metronómica con profármacos de camptotecina (p. ej. PEG-Irinotecán) |
CN109608436B (zh) * | 2011-04-08 | 2022-10-11 | 斯法尔制药私人有限公司 | 取代的甲基甲酰基试剂及使用所述试剂改进化合物物理化学和/或药代动力学性质的方法 |
JP6284541B2 (ja) * | 2012-11-28 | 2018-02-28 | ネクター セラピューティクス | 長時間作用型トポイソメラーゼi阻害薬による乳癌治療の有効性を評価及び予測する方法 |
US20160250177A1 (en) * | 2015-02-17 | 2016-09-01 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
EP3463298B1 (en) | 2016-06-02 | 2021-09-01 | Innopharmax, Inc. | Metronomic oral gemcitabine for cancer therapy |
CN106539557A (zh) * | 2016-10-08 | 2017-03-29 | 西安交通大学 | 一种基于恒速静脉输入的药代动力学参数的测定方法 |
EP3852793A4 (en) | 2018-09-17 | 2022-07-13 | The Children's Hospital Of Philadelphia | MACROMOLECULAR POLYMER-BASED PRODRUGS |
CN115317486B (zh) * | 2022-08-17 | 2024-04-19 | 南昌大学 | 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
IL117684A (en) | 1995-04-07 | 2002-02-10 | Pharmacia & Upjohn Inc | Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds |
US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JP3737518B2 (ja) | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー, エル.ピー. | 水溶性パクリタキセルプロドラッグ |
US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
AU772074B2 (en) | 1999-04-28 | 2004-04-08 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
WO2001046291A1 (en) | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
US6629995B1 (en) | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
MXPA03000481A (es) | 2000-07-21 | 2004-09-09 | Schlumberger Technology Bv | Metodos de resonancia magnetica nuclear para extraer informacion sobre un fluido en una formacion rocosa. |
JP2004514701A (ja) | 2000-11-30 | 2004-05-20 | ネクター セラピューティクス エーエル,コーポレイション | トリアジン誘導体の水溶性ポリマー複合体 |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US7401013B2 (en) | 2001-10-15 | 2008-07-15 | Lockheed Martin Corporation | Method to optimize test data |
WO2003037384A2 (en) | 2001-10-29 | 2003-05-08 | Nektar Therapeutics Al, Corporation | Polymer conjugates of protein kinase c inhibitors |
DE60219677T2 (de) | 2001-10-30 | 2008-05-15 | Nektar Therapeutics Al, Corp., Huntsville | Wasserlösliche polymerkonjugate von retinoesäure |
WO2003049760A1 (en) * | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
EP1531851B1 (en) | 2002-06-06 | 2011-12-14 | University of Washington | Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
KR20140070676A (ko) | 2002-09-06 | 2014-06-10 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
PT1675622T (pt) | 2003-09-17 | 2017-09-19 | Nektar Therapeutics | Pró-fármacos de polímeros de múltiplos braços |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
WO2007098091A2 (en) | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
US7928095B2 (en) | 2007-02-09 | 2011-04-19 | Enzon Pharmaceuticals, Inc. | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
CN101199857B (zh) | 2007-12-12 | 2011-04-13 | 中国药科大学 | mPEG-PLA-喜树碱类药物的结合物 |
ES2744975T3 (es) | 2008-09-23 | 2020-02-27 | Nektar Therapeutics | Método de dosificación metronómica con profármacos de camptotecina (p. ej. PEG-Irinotecán) |
-
2009
- 2009-09-23 ES ES09789364T patent/ES2744975T3/es active Active
- 2009-09-23 MX MX2011003063A patent/MX2011003063A/es active IP Right Grant
- 2009-09-23 WO PCT/US2009/005284 patent/WO2010036335A1/en active Application Filing
- 2009-09-23 EP EP09789364.8A patent/EP2349346B1/en active Active
- 2009-09-23 DK DK09789364.8T patent/DK2349346T3/da active
- 2009-09-23 LT LTEP09789364.8T patent/LT2349346T/lt unknown
- 2009-09-23 CA CA2736939A patent/CA2736939C/en active Active
- 2009-09-23 CN CN2009801371326A patent/CN102164617A/zh active Pending
- 2009-09-23 PT PT97893648T patent/PT2349346T/pt unknown
- 2009-09-23 AU AU2009297091A patent/AU2009297091B2/en active Active
- 2009-09-23 SI SI200932010T patent/SI2349346T1/sl unknown
- 2009-09-23 PL PL09789364T patent/PL2349346T3/pl unknown
- 2009-09-23 RS RS20191501A patent/RS59607B1/sr unknown
- 2009-09-23 US US13/120,551 patent/US8906353B2/en active Active
- 2009-09-23 HU HUE09789364A patent/HUE047352T2/hu unknown
- 2009-09-23 JP JP2011527834A patent/JP2012503602A/ja not_active Withdrawn
- 2009-09-23 KR KR1020117005982A patent/KR20110063457A/ko active Search and Examination
-
2011
- 2011-03-23 IL IL211888A patent/IL211888A/en active IP Right Grant
-
2014
- 2014-11-17 JP JP2014232556A patent/JP6076317B2/ja active Active
- 2014-11-26 US US14/555,440 patent/US9801873B2/en active Active
-
2016
- 2016-09-26 JP JP2016186670A patent/JP2016216510A/ja not_active Withdrawn
-
2017
- 2017-10-03 US US15/723,981 patent/US10525051B2/en active Active
-
2019
- 2019-09-17 CY CY20191100970T patent/CY1122208T1/el unknown
- 2019-11-26 HR HRP20192120TT patent/HRP20192120T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009297091A1 (en) | 2010-04-01 |
US10525051B2 (en) | 2020-01-07 |
US20110269789A1 (en) | 2011-11-03 |
JP2015034180A (ja) | 2015-02-19 |
DK2349346T3 (da) | 2019-10-07 |
CA2736939A1 (en) | 2010-04-01 |
CY1122208T1 (el) | 2020-11-25 |
CA2736939C (en) | 2021-09-14 |
EP2349346B1 (en) | 2019-08-28 |
EP2349346A1 (en) | 2011-08-03 |
US20180028525A1 (en) | 2018-02-01 |
JP2012503602A (ja) | 2012-02-09 |
HUE047352T2 (hu) | 2020-04-28 |
US20150087668A1 (en) | 2015-03-26 |
IL211888A0 (en) | 2011-06-30 |
WO2010036335A1 (en) | 2010-04-01 |
IL211888A (en) | 2015-08-31 |
US8906353B2 (en) | 2014-12-09 |
KR20110063457A (ko) | 2011-06-10 |
ES2744975T3 (es) | 2020-02-27 |
PL2349346T3 (pl) | 2020-03-31 |
SI2349346T1 (sl) | 2019-12-31 |
JP2016216510A (ja) | 2016-12-22 |
LT2349346T (lt) | 2019-09-25 |
RS59607B1 (sr) | 2020-01-31 |
PT2349346T (pt) | 2019-10-24 |
MX2011003063A (es) | 2011-04-21 |
JP6076317B2 (ja) | 2017-02-08 |
CN102164617A (zh) | 2011-08-24 |
AU2009297091B2 (en) | 2015-03-05 |
US9801873B2 (en) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192120T1 (hr) | Postupak metronomskog doziranja kamptotecinskih prolijekova (e.g.peg-irinotekan) | |
HRP20171094T1 (hr) | Višestruko razgranati polimerni prolijekovi | |
ES2380107T3 (es) | Combinación de inmunogenoterapia y quimioterapia para el tratamiento del cáncer y enfermedades hiperproliferativas | |
RU2010137032A (ru) | Конъюгаты паклитаксела с полимером и способы лечения рака | |
HRP20201866T1 (hr) | Formulacije protutijela za her2 za supkutanu primjenu | |
JP2010514787A5 (hr) | ||
RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
CO6241170A2 (es) | Administracion de oligonucleotidos antisentido complementarios a la apolipoproteina b humana | |
JP2014240439A5 (hr) | ||
JP2013527233A5 (hr) | ||
RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
JP2016536352A5 (hr) | ||
RU2019133284A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
Kang et al. | In vivo evaluation of oral anti-tumoral effect of 3, 4-dihydroquinazoline derivative on solid tumor | |
WO2009010287A3 (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
ES2327617T3 (es) | Una combinacion que comprende combrestastatina y agentes anticancerosos. | |
WO2014160216A3 (en) | Dual targeting anticancer agents | |
JP2014523398A5 (hr) | ||
JP2018522028A5 (hr) | ||
JP2012503602A5 (hr) | ||
WO2017184086A1 (en) | Method of treating liver cancer | |
JP2009501230A5 (hr) | ||
JP2007277240A5 (hr) | ||
DE602007012904D1 (de) | Neue 2',3'-methylidenacetyladenosine prodrugs zur | |
JP2007523123A5 (hr) |